EDX MEDICAL GROUP PLC - Investor Presentation

EDX Medical Group PLC delivered an investor presentation outlining significant progress in the development and commercialisation of its ultra-precision diagnostic tests, with a focus on cancer, cardiovascular and infectious diseases. Founder and Chief Scientific Officer Sir Chris Evans highlighted the company's transition from product development to revenue generation, with management anticipating more than £2 million in expected revenues to be announced in the coming quarter. Key developments include the commercial availability of advanced bowel and testicular cancer diagnostics, chemotherapy sensitivity testing, liquid biopsy services and a ventilator-associated pneumonia test currently used at Addenbrooke’s Hospital. EDX Medical also outlined its expanding corporate health screening business, including a contract with Arnold Clark Group covering its 8,500 employees, alongside discussions with several other major employers. The Scottish Prostate Cancer Initiative, targeting 25,000 men, is nearing completion and is supporting the development of a new prostate cancer diagnostic test. Looking ahead, the company expects to launch additional ovarian cancer, prostate cancer and sepsis tests in 2027, targeting a portfolio of 10–15 revenue-generating products. Strategic partnerships with Thermo Fisher Scientific, NHS trusts and leading healthcare providers support its growth strategy, while its Cambridge laboratory capabilities and regulatory expertise provide opportunities for international expansion. Management anticipates accelerating revenue growth over the next 12 months, initially driven by UK commercialisation before expanding into European and US markets through distribution and licensing partnerships. EDX Medical remains focused on scaling its diagnostic portfolio, building recurring revenue streams and establishing a high-growth, commercially sustainable precision healthcare business.